Artiva Biotherapeutics, Inc.
ARTV
$2.47
$0.020.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -65.37M | -61.28M | -32.53M | -25.97M | -28.72M |
| Total Depreciation and Amortization | 2.43M | 2.41M | 2.34M | 2.28M | 2.27M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.24M | 8.91M | 7.90M | 6.78M | 7.30M |
| Change in Net Operating Assets | -325.00K | -1.10M | -27.91M | -31.36M | -28.28M |
| Cash from Operations | -55.03M | -51.06M | -50.19M | -48.27M | -47.43M |
| Capital Expenditure | -642.00K | -1.21M | -1.30M | -1.41M | -3.26M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -119.82M | -120.95M | 9.27M | -12.92M | -22.72M |
| Cash from Investing | -120.46M | -122.17M | 7.97M | -14.33M | -25.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -149.00K | -116.00K | -78.00K | -- | -- |
| Issuance of Common Stock | 166.56M | 166.54M | 22.00K | 10.00K | 10.00K |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | 0.00 | -12.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.18M | -3.20M | 22.83M | 24.39M | 24.39M |
| Cash from Financing | 162.23M | 163.22M | 22.78M | 24.40M | 24.39M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.27M | -10.00M | -19.45M | -38.20M | -49.01M |